Literature DB >> 768993

Serum and blister fluid anticomplementary activity in pemphigus and bullous pemphigoid. Sucrose density gradient studies.

R E Jordon, F C McDuffie.   

Abstract

By sucrose density gradient ultracentrifugation and standard hemolytic complement assays, complement fixing activity of about 19 S and greater was found in blister fluids of one patient with pemphigus and three of five patients with bullous pemphigoid. Control blister fluids, including experimentally induced blisters, lacked such activity. Complement fixing activity was apparent, however, in 6 of 10 pemphigus sera and in two of five bullous pemphigoid sera tested. The material present in both pemphigus and bullous pemphigoid appears to activate the classical complement pathway.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 768993     DOI: 10.3181/00379727-151-39267

Source DB:  PubMed          Journal:  Proc Soc Exp Biol Med        ISSN: 0037-9727


  9 in total

1.  C1q binding substances in pemphigus and bullous pemphigoid. Detection with a [131I] C1q binding assay.

Authors:  G Tappeiner; K G Heine; J C Kahl; R E Jordon
Journal:  Clin Exp Immunol       Date:  1977-04       Impact factor: 4.330

Review 2.  Immune complexes in human diseases: a review.

Authors:  A N Theofilopoulos; F J Dixon
Journal:  Am J Pathol       Date:  1980-08       Impact factor: 4.307

Review 3.  Antibody-induced proteinase activation: a proposed mechanism for pemphigus.

Authors:  K H Singer; K Hashimoto; G S Lazarus
Journal:  Springer Semin Immunopathol       Date:  1981-06

Review 4.  Circulating immune complexes in dermatologic disease.

Authors:  T J Lawley; R P Hall
Journal:  Springer Semin Immunopathol       Date:  1981

5.  Serum and blister fluid immune complexes in bullous pemphigoid: detection with C1q and monoclonal rheumatoid factor.

Authors:  R E Jordon; M F Struve; L L Bushkell
Journal:  Clin Exp Immunol       Date:  1981-07       Impact factor: 4.330

6.  FcRn Antagonism Leads to a Decrease of Desmoglein-Specific B Cells: Secondary Analysis of a Phase 2 Study of Efgartigimod in Pemphigus Vulgaris and Pemphigus Foliaceus.

Authors:  Maud Maho-Vaillant; Magdalena Sips; Marie-Laure Golinski; Gestur Vidarsson; Matthias Goebeler; Johanna Stoevesandt; Zsuzsanna Bata-Csörgő; Bianca Balbino; Peter Verheesen; Pascal Joly; Michael Hertl; Sébastien Calbo
Journal:  Front Immunol       Date:  2022-05-18       Impact factor: 8.786

7.  Complement fixation by pemphigus antibody. II. Complement enhanced detachment of epidermal cells.

Authors:  S Kawana; W D Geoghegan; R E Jordon
Journal:  Clin Exp Immunol       Date:  1985-09       Impact factor: 4.330

8.  Circulating immune complexes in cutaneous vasculitis. Detection with C1q and monoclonal rheumatoid factor.

Authors:  S E Mackel; G Tappeiner; H Brumfield; R E Jordan
Journal:  J Clin Invest       Date:  1979-12       Impact factor: 14.808

Review 9.  The relevance of complement in pemphigoid diseases: A critical appraisal.

Authors:  Cristian Papara; Christian M Karsten; Hideyuki Ujiie; Enno Schmidt; Leon F Schmidt-Jiménez; Adrian Baican; Patricia C Freire; Kentaro Izumi; Katja Bieber; Matthias Peipp; Admar Verschoor; Ralf J Ludwig; Jörg Köhl; Detlef Zillikens; Christoph M Hammers
Journal:  Front Immunol       Date:  2022-08-16       Impact factor: 8.786

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.